GlycoMimetics(GLYC) - 2025 Q4 - Annual Results

Crescent Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights ASCEND Phase 1/2 global clinical trial underway to evaluate CR-001 in advanced solid tumors with three additional clinical trials across the portfolio expected to initiate in 2026 Completed $185 million private placement, supporting several key clinical data readouts beginning in Q1 2027 and providing expected cash runway into 2028 Waltham, Mass., February 26, 2026 – Crescent Biopharma, Inc. ("Cresc ...